Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Shares Outstanding (Weighted Average) (2019 - 2025)

BridgeBio Pharma's Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $191.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 2.93% year-over-year to $191.5 million; the TTM value through Dec 2025 reached $191.5 million, up 2.93%, while the annual FY2025 figure was $191.5 million, 2.93% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $191.5 million at BridgeBio Pharma, roughly flat from $191.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $191.9 million in Q3 2025 and bottomed at $138.6 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $157.8 million (2023), against an average of $164.7 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) increased 22.42% in 2021 before it grew 1.56% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $144.4 million in 2021, then rose by 2.16% to $147.5 million in 2022, then increased by 10.39% to $162.8 million in 2023, then increased by 14.3% to $186.1 million in 2024, then rose by 2.93% to $191.5 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Shares Outstanding (Weighted Average) are $191.5 million (Q4 2025), $191.9 million (Q3 2025), and $190.5 million (Q2 2025).